We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · September 28, 2020

Enhanced YB1/EphA2 Axis Signaling Promotes Acquired Resistance to Sunitinib and Metastatic Potential in RCC

Oncogene

 

Additional Info

Oncogene
Enhanced YB1/EphA2 Axis Signaling Promotes Acquired Resistance to Sunitinib and Metastatic Potential in Renal Cell Carcinoma
Oncogene 2020 Sep 01;39(38)6113-6128, H Ruan, S Li, L Bao, X Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading